Participated · Series B · Aug 2026

Mironid develops first-in-class small-molecule LoAc® drug candidates that directly target abnormally high kidney cAMP levels that drive cyst formation in ADPKD. Its lead programmes are focused on treating Autosomal Dominant Polycystic Kidney Disease, a hereditary disorder affecting over 12 million people worldwide with about 50% of patients developing kidney failure by age 60. The company was founded through collaboration between the University of Strathclyde and Heriot-Watt University and is led by CEO Neil Wilkie. Mironid has progressed a series of drug-development programmes targeting specific enzymes to generate differentiated therapies for diseases with high unmet need. The recently closed £34m Series B, which includes an £8.4m equity investment from SNIB and participation from Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde, will fund clinical development and advancement of its lead candidate.

Led · Equity · Jul 2026

QuickBlock develops defence infrastructure products, including rapid-deployment shelter solutions, and is investing in R&D to advance those offerings. The recent financing includes grant support earmarked for R&D activity related to its rapid deployment shelters. Management plans to use the funds to expand into key European markets, boost production capacity, and strengthen commercial capabilities. The company’s capital raise combined equity investment and innovation grants, indicating simultaneous focus on commercialization and technology development. No revenue, user, founding year, or location details were provided in the article.

Participated · Seed · May 2026

Northern Light Microscopy develops the AMIS (Advanced Modular Imaging System), a compact benchtop microscope that combines a proprietary micro-optical light engine with structured illumination to deliver up to eight advanced imaging modes. The AMIS is designed to offer high-throughput and super-resolution imaging across a range of magnifications and illumination wavelengths while integrating into existing lab workflows without protocol changes. The company says the AMIS has outperformed established, significantly more expensive systems in direct comparison studies. Northern Light is also developing LINK imaging software and plans additional hardware modules to expand its product line. The business was founded by Dr Peter Tinning (CEO) and Dr Ralf Bauer (CTO), is supported by Non-Executive Chair Colin Roberts, and is commercialising its technology from Glasgow with regulatory targets and first sales planned ahead of international expansion from 2027.

Participated · Seed · Mar 2026

Regeno designs modular, plug-and-play wind turbines engineered to be serviced from ground level and assembled without cranes or specialist installers. Its design aims to reduce installation and maintenance costs, shorten downtime, and change the economics of wind deployment. Regeno says each unit can cut carbon emissions by up to 1.5 tonnes per year and save users up to 25% on electricity costs. The company plans to commercialise its prototype, run field trials, target farms first, and then expand to larger onshore and offshore wind farms. Regeno intends to use the recent £422K raise to prove the technology and conduct those field trials, followed by another seed round to certify for safety and enable global deployment. The company was founded by solo CEO Adarsh Bhardwaj, who developed the idea during his dissertation at the University of Strathclyde.

Participated · Seed · Jan 2026

Biomarx is building the next generation of genomic laboratory medicine platforms that lower the cost, complexity and skill barriers traditionally associated with next-generation sequencing. Its automated system is designed for rapid, affordable detection of circulating tumour DNA fragments, aiming to reduce health inequalities and speed the clinical adoption of personalised therapies. The company’s first product will be a liquid biopsy test for non-small cell lung cancer, supporting earlier detection and targeted treatment decisions. Fresh capital will allow Biomarx to progress from proof of concept to a minimum viable product, secure ISO 13485 accreditation and run a preliminary lab-based clinical study. Development work will be carried out in Glasgow in collaboration with the University of Strathclyde, leveraging the university’s deep-tech commercialisation ecosystem. Financially, the company has just closed a £700,000 pre-seed round, its first disclosed external funding. These resources position Biomarx to advance towards clinical validation and eventual market entry.